AMDL, Inc. Named to Deloitte LLC Technology Fast 50
October 24 2008 - 10:22AM
PR Newswire (US)
Company Listed Among North America's Fastest-Growing Companies
TUSTIN, Calif., Oct. 24 /PRNewswire-FirstCall/ --
(http://www.amdl.com/) AMDL, Inc. (AMEX:ADL), a vertically
integrated pharmaceutical company with major operations in China
and the US, today announced it has been recognized by Deloitte LLP
as the 6th fastest growing Company in Orange County in the
prestigious Deloitte Technology Fast 50 Program. This
nationally-recognized program is a ranking by Deloitte LLP of the
50 fastest growing technology, media, telecommunications, and life
sciences companies specifically in Orange County and surrounding
areas. The company ranked the Top-50 companies based on the highest
percentage of revenue growth over five years from 2003-2007. AMDL
secured the 6th position by achieving an average 4,100 percent
revenue growth during this period. The Company was also recognized
earlier this week by the Orange County Business Journal as the #1
fastest-growing public Company in Orange County, achieving over
33,440% revenue growth and more than $26 million in sales in the
periods between June 30, 2205 and June 30, 2008. AMDL's President
and CEO Mr. Gary Dreher credits the Company's strong revenue growth
to consistent execution on key business initiatives, including the
successful marketing, sales, and expanded distribution of high
profit products that include the Goodnak(R) anti-aging product
line, Domperidone anti-emetic product and various off-label
pharmaceuticals. Strong sales of these products have driven AMDL's
year-over-year revenue growth by more than 100%, specifically in
the past 24 months. The Company has also hit key business
milestones over the past 12 months that position the Company for
continued growth. This includes success in obtaining regulatory
approval by the United States Food and Drug Administration (US FDA)
for the AMDL ELISA DR-70(R) (FDP) cancer test. "Sustaining high
revenue growth over five years is an exceptional accomplishment,
particularly for an emerging company such as AMDL," said Rob
Lucenti, Managing Partner, Orange County Practice, Deloitte &
Touche LLP. "We commend AMDL for having shown the strength, vision
and tenacity to succeed in today's very competitive life sciences
environment and is proud to honor them to Deloitte's Technology
Fast 50." Mr. Gary Dreher, president and CEO of AMDL commented,
"Making this list is a tremendous honor for AMDL and a reflection
of the hard work and commitment of our China and US-based teams.
Our combined efforts have driven the major advancements in our
business and subsequently our strong financial performance; and
we're focused on continuing the positive path we've paved which
includes achieving our targeted sales goal of $26 million in sales
in the second half of this year and $38 million for fiscal year
2008." To qualify for the Technology Fast 50, companies must have
had operating revenues of at least $50,000 in 2003 and $5,000,000
in 2007, be headquartered in North America, and be a company that
owns proprietary technology or proprietary intellectual property
that contributes to a significant portion of the company's
operating revenues; or devotes a significant proportion of revenues
to the research and development of technology. Using other
companies' technology or intellectual property in a unique way does
not qualify. This year's Orange County Technology Fast 50 program
is sponsored by Cresa Partners, DLD Insurance Brokers, Stradling
Yocca Carlson & Rauth, Union Bank of California, Publicease and
Oracle, in association with the Technology Council of Southern
California. Companies from the regional Technology Fast 50 programs
in the United States and Canada are automatically entered in
Deloitte's Technology Fast 500 program, which ranks North America's
top 500 fastest growing technology, media, telecommunications and
life sciences companies. For more information on Deloitte's
Technology Fast 50 or Technology Fast 500 programs, visit
http://www.fast500.com/. About AMDL: Headquartered in Tustin, CA
with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc.,
along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a
vertically integrated bio-pharmaceutical company devoted to the
research, development, manufacturing, and marketing of diagnostic,
pharmaceutical, nutritional supplement, and cosmetic products. The
company employs approximately 320 people in the U.S. and China. The
Company has an additional 4 pharmaceutical and diagnostic products
under review by various regulatory authorities. Forward Looking
Statements: Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995: The statements contained in this
document include certain predictions and projections that may be
considered forward- looking statements under securities law. These
statements involve a number of important risks and uncertainties
that could cause actual results to differ materially including, but
not limited to, the performance of joint venture partners, as well
as other economic, competitive and technological factors involving
the Company's operations, markets, services, products, and prices.
With respect to AMDL, Inc., except for the historical information
contained herein, the matters discussed in this document are
forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
related to the Company's access to additional capital, competition
and dependence on key management. AMDL Contact: Kristine Szarkowitz
Director-Investor Relations (Tel:) 206.310.5323 DATASOURCE: AMDL,
Inc. CONTACT: Kristine Szarkowitz, Director-Investor Relations,
+1-206-310-5323, Web Site: http://www.amdl.com/
http://www.fast500.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024